Dr. Yang Lu, M.D., PH.D.
Nuclear Medicine (Nuclear Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,621
Licensed in Texas since 2017, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nuclear Medicine Physician primary
TX license R1575 (first issued 2017; active) · IL license 336090464
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,621
- Services billed
- 1,804
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Nuclear medicine study from skull base to mid-thigh with ct scan | 544 | 512 |
| Dxa bone density measurement of hip, pelvis, spine | 532 | 531 |
| Nuclear medicine study of bone and/or joint whole body | 475 | 437 |
| Nuclear medicine study whole body with ct scan | 86 | 85 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 69 | 69 |
| Radioactive drug therapy through a vein | 56 | 52 |
| Nuclear medicine study, whole body | 39 | 37 |
| Nuclear medicine study of heart pumping function by labeling red blood cells with measurement of internal blood volume ejected with every beat over multiple cycles | 38 | 37 |
| Nuclear medicine study of lymphatic system | 36 | 36 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 30 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $62,486 in research payments for these studies, mostly to the institutions running them.
- A pilot study to assess the clinical utility of pylarify pet-ct for detecting metastasis in pancreatic cancer, hepatocellular carcinoma and breast cancer
Progenics Pharmaceuticals, Inc. - INVFE
Progenics Pharmaceuticals, Inc. - A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
Blue Earth Diagnostics · Terminated · NCT06015295
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.